Phase II Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal Cell Carcinoma

BACKGROUND: Patients with sarcomatoid renal cell carcinomas (sRCC) have poor outcomes and limited treatment options. Pre-clinical and clinical data suggest susceptibility to cytotoxic agents and vascular endothelial growth factor-targeted therapies. We designed a phase II trial to evaluate the effic...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Genitourin Cancer
Autori principali: Maiti, Abhishek, Nemati-Shafaee, Maryam, Msaouel, Pavlos, Pagliaro, Lance C., Jonasch, Eric, Tannir, Nizar M., Shah, Amishi Y.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5809227/
https://ncbi.nlm.nih.gov/pubmed/28870517
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2017.07.028
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi